Skip to main content

Table 3 Factors related to GSM treatment adherence during COVID-19 confinement

From: Women's knowledge about the genitourinary syndrome of menopause: adherence to its treatments in the COVID-19 era in a sample of them: COMEM-GSM study

  Good compliancea (n = 56) Poor complianceb (n = 148) p value
Age    
Median (RIQ*) 58 (53.7–60.2) 59 (54–60) 0.988
Years of menopause    
Median (RIQ) 50 (49–52) 50 (49–52) 0.693
Sexually active before confinement    
Yes 48 (85.7) 128 (86.5) 0.919
No 8 (14.3) 20 (13.5)  
Level of education    
Basic-medium 28 (50) 84 (56.8) 0.541
Higher 28 (50) 64 (43.2)  
Decreased sexual activity    
Yes 12 (21.4) 100 (67.6) < 0.001
No 44 (78.6) 48 (32.4)  
Indicated treatments    
Lubricants, moisturizers 12 (21.4) 36 (24.3) 0.218
Local estrogens 32 (57.1) 88 (59.5)  
Prasterone 4 (7.1) 16 (10.8)  
Ospemifene 8 (14.3) 4 (2.7)  
MHT - 4 (2,7)  
COVID infection    
Yes 16 (28.6) 8 (5.4) 0.003
No 40 (71.4) 140 (94.6)  
  1. MTH menopause hormone therapy
  2. *RIQ: Interquartile range
  3. aCompliance was considered to be good if the 4 questions of the Morinsky–Green–Levine test were answered correctly, as follows: No/Yes/No/No [8]
  4. bCompliance was considered to be poor if any of these 4 questions were answered incorrectly